Skip to content

Incyte INCY Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.1B-43.5%
Pfizer logo
PfizerPFE
$2.62B+12.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$65.59M-20.6%
Gilead Sciences logo
Gilead SciencesGILD
$2.54B+44.8%
Geron logo
GeronGERN
-$62.91M-31.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$48.94M-139%

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.7%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$23.32B+78.0%
Enterprise value$19.89B+77.9%
P/E16.3×+1.2×
P/S4.4×+1.5×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp
FCF margin28.2%+19.7pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's operating cash flow?
Incyte (INCY) reported operating cash flow of $369.35M in Q1 2026.
How has Incyte's operating cash flow changed year-over-year?
Incyte's operating cash flow increased by 38.8% year-over-year, from $266.07M to $369.35M.
What is the long-term trend for Incyte's operating cash flow?
Over 4 years (2021 to 2025), Incyte's operating cash flow has grown at a 17.2% compound annual growth rate (CAGR), from $749.49M to $1.41B.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.